Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00959 ...
Drug Name Methylprednisolone
Molecular Weight 374.4706
Molecular Formula C22H30O5
CAS Number 83-43-2
SMILES [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C
External Links
DRUGBANK DB00959
PubChem Compound 6741
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 1.525 - 1.525 - ChemSpider
Melting Point 232.5 ℃ 232.5 ℃ PhysProp
Water Solubility 120.0 mg/L 120 mg/L YALKOWSKY,SH & DANNENFELSER,RM 1992)
Log S -2.99 - -2.99 - ADME Research, USCD

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Bioavailability 89.9 % 89.9 % PO, oral; DRUGBANK
Bioavailability 14.2 % 14.2 % Rectal Administration; DRUGBANK
Bioavailability 82.0 % 82±13 % PO, oral; increasing doses ↑ ; The Pharmacological Basis of Therapeutics
C Max 178.0 ng/ml 178±44 ng/ml PO, oral; Male, men; adults; normal,healthy; The Pharmacological Basis of Therapeutics
C Max 225.0 ng/ml 225±44 ng/ml intravenous injection, IV; Male, men; adults; normal,healthy; The Pharmacological Basis of Therapeutics
T Max 1.6 h 1.64±0.64 h PO, oral; Male, men; adults; normal,healthy; The Pharmacological Basis of Therapeutics
Clearance 0.34 L/h/kg 336.0 ml/h/kg Plasma clearance; DRUGBANK
Clearance 0.37 L/h/kg 6.2±0.9 ml/min/kg  Female, women ↑ ;Hepatic cirrhosis, cirr → ;rheumatoid arthritis → ;Obesity ↑ ;chronic respiratory insufficiency → ;nephritic syndrome → ; The Pharmacological Basis of Therapeutics
Clearance 0.37 L/h/kg 6.1 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 1.4 L/kg 1.38 L/kg Average volume of distribution; DRUGBANK
Volume of Distribution 1.2 L/kg 1.2±0.2 L/kg  Female, women → ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia → ;rheumatoid arthritis → ;Obesity ↓ ;chronic respiratory insufficiency → ;nephritic syndrome → ; The Pharmacological Basis of Therapeutics
Volume of Distribution 1.2 L/kg 1.2 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 2.3 h 2.3 h DRUGBANK
Half-life 2.3 h 2.3±0.5 h  Female, women ↓ ;nephritic syndrome → ;RD, renal impairment, Renal disease，including uremia → ;rheumatoid arthritis → ;chronic respiratory insufficiency → ;Hepatic cirrhosis, cirr → ;Obesity ↑ ; The Pharmacological Basis of Therapeutics
Half-life 2.3 h 2.3 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 4000.0 mg/kg >4 g/kg PO, oral; Rattus, Rat; DRUGBANK
Toxicity LD50 2292.0 mg/kg 2292.0 mg/kg Intraperitoneal, IP; mouse; DRUGBANK
Toxicity LD50 100.0 mg/kg 100.0 mg/kg Intraperitoneal, IP; Rattus, Rat; DRUGBANK
Eliminate Route 28.0 % 25-31 % Urinary excretion; dog; DRUGBANK
Eliminate Route 48.0 % 44-52 % Faeces excretion; Infants; DRUGBANK
Eliminate Route 4.9 % 4.9±2.3 % Urinary excretion; Unchanged drug; Hepatitis, Hep → ; The Pharmacological Basis of Therapeutics
Protein Binding 76.8 % 76.8 % DRUGBANK
Protein Binding 78.0 % 78±3 %  Female, women → ;Hepatic cirrhosis, cirr ↓ ; The Pharmacological Basis of Therapeutics

Maximum Dosage

Not Available

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1